Pasithea Therapeutics (KTTA) Enterprise Value (2020 - 2026)
Pasithea Therapeutics (KTTA) posted Enterprise Value of -$50.5 million for Q1 2026, up 8.68% sequentially from -$55.3 million in Q4 2025, and down 845.49% YoY from $6.8 million in Q1 2025.
Pasithea Therapeutics (KTTA) Enterprise Value (2020 - 2026) Analysis & Trends
Pasithea Therapeutics has reported Enterprise Value for 7 years, with the latest figure at -$50.5 million in Q1 2026.
- Quarterly Enterprise Value fell 845.49% year-over-year to -$50.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$50.5 million (down 845.49% YoY) and the FY2025 annual result came in at -$55.3 million, down 698.83% from the prior year.
- Enterprise Value climbed to -$50.5 million in Q1 2026 per KTTA's latest filing, from -$55.3 million in the prior quarter.
- Over five years, Enterprise Value peaked at -$4.2 million in Q3 2025 and troughed at -$55.3 million in Q4 2025.
- A 5-year average of -$24.9 million and a median of -$19.7 million in 2023 frame the typical range for Enterprise Value.
- The sharpest annual moves came in 2024 and 2026: Enterprise Value surged 73.48% in 2024, then tumbled 845.49% in 2026.
- Over 5 years, Enterprise Value stood at -$33.1 million in 2022, then soared by 50.64% to -$16.3 million in 2023, then jumped by 57.61% to -$6.9 million in 2024, then tumbled by 698.83% to -$55.3 million in 2025, then grew by 8.68% to -$50.5 million in 2026.
- According to Business Quant data, Enterprise Value over the past three periods registered -$50.5 million, -$55.3 million, and -$4.2 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Enterprise Value (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | -7.85 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | -7.99 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | -5.18 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | -5.14 Bn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | -5.10 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | -3.31 Bn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | -1.16 Bn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 2.12 Bn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -18.39 Bn |
| 10 | Pasithea Therapeutics | 15.13 Mn | 15.13 Mn | - | -45.80 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -50.50 Mn |
| Dec 31, 2025 | -55.30 Mn |
| Sep 30, 2025 | -4.22 Mn |
| Jun 30, 2025 | -6.20 Mn |
| Mar 31, 2025 | -5.34 Mn |
| Dec 31, 2024 | -6.92 Mn |
| Sep 30, 2024 | -9.36 Mn |
| Jun 30, 2024 | -7.10 Mn |
| Mar 31, 2024 | -12.01 Mn |
| Dec 31, 2023 | -16.33 Mn |
| Sep 30, 2023 | -19.68 Mn |
| Jun 30, 2023 | -26.77 Mn |
| Mar 31, 2023 | -29.91 Mn |
| Dec 31, 2022 | -33.09 Mn |
| Sep 30, 2022 | -42.40 Mn |
| Jun 30, 2022 | -47.94 Mn |
| Mar 31, 2022 | -50.32 Mn |
| Dec 31, 2021 | -52.97 Mn |
| Sep 30, 2021 | -20.57 Mn |
| Dec 31, 2020 | -243,650.00 |